A combination of the drugs Kalydeco (ivacaftor) and lumacaftor, which has not yet been approved by the Food and Drug Administration (FDA), can successfully treat the underlying cause of cystic fibrosis for patients age 12 and older with two copies of the F508del gene mutation (the most common form of the disease), according to two phase 3 clinical trials published in the New England Journal of Medicine. Read more.